Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 132 results for multiple sclerosis

  1. Glatiramer acetate depot for multiple sclerosis [TSID10620]

    Topic prioritisation

  2. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    Question Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory notes(if...

  3. What is the clinical and cost effectiveness of cognitive rehabilitation for people with Multiple sclerosis (MS)?

    people with Multiple sclerosis (MS)? Any explanatory notes(if applicable) Cognitive impairment affects 43–70% of people...

  4. What non-pharmacological interventions are effective in reducing spasticity in people with Multiple Sclerosis (MS)?

    with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Spasticity is a common symptom affecting up to 80% of...

  5. Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]

    Topic prioritisation

  6. Tolebrutinib for treating primary progressive multiple sclerosis [TSID12166]

    Topic prioritisation

  7. What is the optimal frequency, intensity and form of rehabilitation for mobility problems in people with Multiple Sclerosis (MS)?

    people with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Reduced mobility is one of the most common...

  8. Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive MS with continued relapses?

    methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive...

  9. Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

    Topic prioritisation

  10. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes....

  11. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

  12. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

  13. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.

  14. Ocrelizumab for treating relapsing–remitting multiple sclerosis in people 10 to 17 years [TSID12164]

    Topic prioritisation